Biofrontera Inc. (BFRI)

NASDAQ: BFRI · Real-Time Price · USD
0.8130
-0.0347 (-4.09%)
At close: Mar 28, 2025, 4:00 PM
0.8455
+0.0325 (3.99%)
After-hours: Mar 28, 2025, 5:13 PM EDT
-4.09%
Market Cap 7.21M
Revenue (ttm) 37.32M
Net Income (ttm) -17.76M
Shares Out 8.87M
EPS (ttm) -3.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,472
Open 0.8400
Previous Close 0.8477
Day's Range 0.8130 - 0.8390
52-Week Range 0.6510 - 2.4300
Beta 0.31
Analysts Strong Buy
Price Target 7.00 (+761.01%)
Earnings Date Mar 21, 2025

About BFRI

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate seve... [Read more]

Sector Healthcare
IPO Date Oct 29, 2021
Employees 85
Stock Exchange NASDAQ
Ticker Symbol BFRI
Full Company Profile

Financial Performance

In 2024, Biofrontera's revenue was $37.32 million, an increase of 9.54% compared to the previous year's $34.07 million. Losses were -$17.76 million, -11.78% less than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for BFRI stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(761.01% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI) Q4 2024 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Andrew Barwicki - IR Representative Hermann Luebbert - CEO, Chairman, and Founder Fred ...

7 days ago - Seeking Alpha

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass.

7 days ago - GlobeNewsWire

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of...

10 days ago - GlobeNewsWire

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today an...

17 days ago - GlobeNewsWire

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

2 months ago - GlobeNewsWire

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

3 months ago - GlobeNewsWire

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photo...

4 months ago - Accesswire

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

4 months ago - GlobeNewsWire

Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Conference Call November 14, 2024 10:00 AM ET Company Participants Andrew Barwicki - Investor Relations Hermann Luebbert - Chief Executive Officer, Cha...

4 months ago - Seeking Alpha

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

4 months ago - GlobeNewsWire

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, ...

5 months ago - Accesswire

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

5 months ago - GlobeNewsWire

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

5 months ago - GlobeNewsWire

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic pro...

6 months ago - GlobeNewsWire

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that manageme...

6 months ago - Accesswire

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI) Q2 2024 Earnings Conference Call August 15, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - CEO, Chairman and Fou...

8 months ago - Seeking Alpha

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported...

8 months ago - GlobeNewsWire

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financ...

8 months ago - Accesswire

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the laun...

9 months ago - GlobeNewsWire

Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI) Q1 2024 Earnings Conference Call May 16, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer,...

11 months ago - Seeking Alpha

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company special...

11 months ago - Accesswire

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will repor...

11 months ago - Accesswire

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

WOBURN, MA / ACCESSWIRE / May 3, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced th...

11 months ago - Accesswire

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announce...

1 year ago - Accesswire

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha